With the efficacy of PrEP now proven, attention at CROI 2011 turned to adherence and safety.
Initial proof-of-concept trials showed moderate effectiveness for both topical and oral pre-exposure prophylaxis (PrEP) and demonstrated a strong correlation between adherence and effectiveness (Science 2010; 329:5996 and N Engl J Med 2010; 363:2587). At CROI 2011, we heard more about adherence to PrEP, as well as safety.
Adherence
In the iPrEx trial, the absence of study drug in the bloodstream was a strong predictor of HIV acquisition. However, drug levels did not correlate with other adherence measures, including self-report, pill count, and refill-based assessments [Amico R et al. Abstract 95LB]. A detailed analysis showed that detection of intracellular tenofovir and FTC was independently associated with age ≥25 and with report of unprot…
Author
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes